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A B S T R A C T
Purpose
The combination of interferon alfa (IFN) and isotretinoin has shown a direct antiproliferative
effect on human melanoma cell lines, but it remained unclear whether this combination is
more effective than IFN alone in patients with metastatic melanoma. We evaluated safety
and efficacy of IFN and isotretinoin compared with IFN alone as adjuvant treatment in
patients with primary malignant melanoma stage IIA and IIB.
Patients and Methods
In a prospective, randomized, double-blind, placebo-controlled trial, 407 melanoma patients
in stage IIA (301 patients) and IIB (106 patients) were randomly assigned to either IFN
and isotretinoin (isotretinoin group; 206 patients) or IFN and placebo (placebo group;
201 patients) after excision of the primary tumor. IFN was administered three times a
week at a dose of 3 million units subcutaneously for 24 months. Isotretinoin at a dose of
20 mg for patients  73 kg, 30 mg for patients greater than 73 kg, or placebo daily for
24 months.
Results
A scheduled interim analysis revealed no significant differences in survival rates, with the
isotretinoin group and the placebo group showing 5-year disease-free survival rates of 55%
(95% CI, 46% to 65%) and 67% (95% CI, 59% to 75%), respectively, and overall 5-year
survival rates of 76% (95% CI, 67% to 84%) and 81% (95% CI, 74% to 88%), respectively.
The trial was stopped for futility.
Conclusion
The addition of isotretinoin to an adjuvant treatment of low-dose IFN in patients with stage
IIA and IIB melanoma had no significant effect on disease-free or overall survival and is
therefore not recommended.
J Clin Oncol 23:8655-8663. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Interferons are a group of naturally occurring
proteins with a large spectrum of biologic
activities including antiviral, immunomodu-
latory, antiproliferative, and differentiation-
inducing effects.1-4 Treatment with interferon
alfa (IFN) has been shown to prolong
disease-free survival in melanoma pa-
tients at moderate to high risk of develop-
ingmetastatic disease after surgery (American
Joint Committee on Cancer [AJCC] stage
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IIA to III)5 and in some studies, to prolong overall survival
in this patient population.6-14
As derivates of vitamin A, retinoids also show a wide
spectrum of biologic activities, including immunemodula-
tion, sebosuppression, and effects on cell proliferation and
cell differentiation in both melanoma and nonmelanoma
cell lines.15-19 In some clinical trials evaluating isotretinoin
and etretinate for treatment of nonmelanoma skin cancers,
tumor suppression was achieved,18,20 although isotretinoin
was ineffective in preventing basal cell carcinomas in a large
study with 981 patients.21 However, in an adjuvant treat-
ment study,22 vitamin A was not significantly better than
observation alone in prolonging disease-free survival or
overall survival in patients with primarymelanomas thicker
than 0.75 mm and with clinically negative lymph nodes.
Because the combination of IFN and retinoic acid has
shown a direct antiproliferative effect on malignant human
cell lines, especially melanoma cell lines,23-26 several phase
II clinical trials have been performed to evaluate the com-
bination therapy in patients with nonmelanoma skin can-
cers and in patients with metastatic melanoma.27-36 In
patients with metastatic melanoma disease, the effective-
ness of the combination of IFN and retinoic acid was
unclear: some studies demonstrated efficacy, with total
response from 20% to 30%,27,32,33 whereas other studies
reported no or extremely low response to the combina-
tion therapy.30,35,36
Motivated by the positive studies, we designed a pro-
spective, randomized, multicenter, double-blind, placebo-
controlled trial comparing adjuvant combination therapy
of IFN and isotretinoin with adjuvant therapy of IFN
alone in patients with primary malignant melanoma stage
IIA and IIB AJCC/International Union Against Cancer
[UICC] 198837 to investigate whether the addition of
isotretinoin to IFN resulted in greater treatment efficacy.
PATIENTS AND METHODS
Study Design
The study was a prospective, 24-month, randomized, multi-
center, double-blind, placebo-controlled, parallel-group trial
evaluating the efficacy of adjuvant therapy of 3million units (MU)
of IFN given subcutaneously three times a week in combination
with daily oral isotretinoin (Roaccutan; Roche, Vienna, Austria;
isotretinoin group) compared with IFN alone (placebo group)
for treatment of primary melanoma in stage IIA/IIB. The primary
end point of the study was disease-free survival, and the secondary
end points were overall survival and evaluation of quality of life
during treatment. Disease-free survival was chosen as primary end
point to get a sufficient number of events for the required power,
with a limited sample size and duration of the trial. The study was
sponsored by Roche Austria GmbH (Vienna, Austria). Twenty
centers in Austria, Hungary, the Netherlands, and Greece partici-
pated. Patient recruitment was started on October 16, 1996, and
stopped on December 31, 2002.
Four hundred seven melanoma patients who met the inclu-
sion/exclusion criteria were randomly assigned to receive either
IFN and isotretinoin (isotretinoin group; 206 patients) or IFN
and placebo (placebo group; 201 patients). Treatment was started
within 16 weeks after completion of all surgical interventions,
including primary and secondary tumor excision.
IFN was administered subcutaneously at a dose of 3 MU 3
times a week for 24 months. Isotretinoin was given daily for 24
months at a dose of 20 mg (two 10-mg capsules) for patients with
weight 73 kg and at a dose of 30 mg (three 10-mg capsules) for
patients with weight greater than 73 kg. Patients in the placebo
group received an equivalent number of matching placebo cap-
sules daily for 24 months.
Radiotherapy or concomitant medication with tetracyclines,
other immunotherapy, chemotherapy, or any investigational drug
was disallowed during the trial. Patients were permitted to use
paracetamol/indomethacine to ameliorate the flu-like symptoms
associated with IFN therapy.
The following assessments were made at baseline after ran-
domization, once a month during the first three months, then at
3-month intervals: CBC and blood chemistry (including leuko-
cytes, hemoglobin, WBC differential count, platelets, total biliru-
bin, liver function enzymes, alkaline phosphatase, creatine
phosphokinase, renal function, cholesterol, and triglycerides). Ad-
ditionally, only at baseline, the following laboratory tests were
performed: total protein, blood glucose, lactate dehydrogenase
acid, high- and low-density lipoproteins, thyroid-stimulating hor-
mone, serum electrolytes, and urine analysis. Chest x-ray, ultra-
sonography of the abdomen and the draining lymph nodes, and
x-ray of the cervical spine, thoracic spine, lumbar spine, one knee,
one ankle, and both forearms were required at baseline and at the
end of treatment. Blood pressure and weight were measured at
baseline and every 3 months. A visual analog scale was used to
assess quality of life every 3 months during treatment and every 6
months after treatment cessation.
The trial protocol and five amendments were reviewed and
approved by local ethics committees at the participating sites. The
study was overseen by a Data Safety Monitoring Committee con-
sisting of two clinical pharmacologists, a statistician, a dermatol-
ogist, and a retired expert on isotretinoin, none of whom was
otherwise involved in the study. The Data Safety Monitoring
Committee met regularly to review safety data, trial conduct, and
protocol violations. The study was conducted in accordance with
the Declaration of Helskinki and with Good Clinical Practice
guidelines. All patients received a detailed explanation of the po-
tential risks and benefits of the study and provided signed in-
formed consent before participating in the study.
Patients
Initially all patients between 18 and 75 years of age with
primary melanoma in stage IIA or IIB as defined by AJCC/UICC
1988 (IIA, localizedmelanoma with tumor thickness of 1.51 to 4.0
mm or Clark level IV; IIB, localized melanoma 4.0 mm tumor
thickness or Clark level V)37 were eligible for the trial. Because the
performance of sentinel node biopsy in routine settings was
steadily increasing after the start of the study, the protocol was
amended (amendment 2; May 10, 1999) to permit patients to be
enrolled after sentinel node biopsy, provided that they were senti-
nel node–negative or, in case of positivity, that positivity revealed
only micrometastasis and that subsequent radical lymphadenec-
tomy showed negative lymph nodes.
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The patients had to meet also the following inclusion
criteria: baseline laboratory results including leukocyte count
(WBC)  3.0  109/L, platelets count  100  109/L, hemo-
globin  10 g/100 mL (1 dL), cholesterol  300 mg/dL, and
triglycerides  250 mg/dL. Women of child-bearing potential
were informed orally about the teratogenic effect of retinoids
and given a patient information sheet. Women of child-bearing
potential were required to use an accepted method of birth
control for at least 1 month before beginning therapy, during
treatment, and for a minimum of 3 months after discontinua-
tion of therapy. Women of child-bearing potential were also
required to have a serum pregnancy test performed by a physi-
cian within 2 days of treatment initiation and monthly until 3
months after treatment cessation.
Pregnant or lactating women, individuals younger than 18
years, and individuals with psychiatric disorders, depression, or
seizure disorders or compromised CNS function were excluded.
Persons with history or presence of autoimmune disease, with
serious infections within previous 28 days, and with severe sys-
temic disease (such as cardiac disease, severe liver disease, severe
renal disease, or myeloid dysfunction) were also excluded. Prior
immunotherapy, chemotherapy, or therapy with an investiga-
tional drug within 3months of study initiation was not permitted.
Presence of neoplastic disease within the previous 5 years was an
exclusion criterion, except for basal cell carcinoma of the skin,
actinic keratoses, and carcinoma-in-situ of the skin or cervix,
provided that these had been cured by surgery.
Randomization
Patients were centrally randomized by the Department of
Medical Statistics at the University of Vienna. Major inclusion
criteria were checked before randomization. A biased coin ran-
domization was applied to balance treatment groups for sex, stage
(IIA v IIB), age ( 50 v 50 years), weight ( 73 v 73 kg) and
study center. The allocation probabilities to the two treatments
were calculated on the basis of an imbalance score defined as a
weighted sum of the differences of the treatment allocation num-
bers in the strata defined by the five risk factors. Unconstrained
randomization was used in the beginning.38
Blinded medication was prepared by the galenic division of
Hoffmann-La Roche, Basel, Switzerland, and stored at Roche
(where there was no access to the code). The randomization pro-
cess generated a patch number of the patient’s blindedmedication,
which was printed and faxed to Roche for distribution to the
recruiting center. In this way, all patients and investigators were
blinded regarding treatment allocation. Each center received a
sealed envelope containing patient number and treatment alloca-
tion, which could be opened only in case of a serious adverse event
that necessitated disclose of the treatment. A total of 20 envelopes
were opened before the end of the study or were missing when the
study was terminated.
Compliance
IFN was given monthly under the trade name used in the
participating countries and injected by the patients themselves.
Study participants were instructed to store IFN in the refrigera-
tor from 2°C to 8°C. Patients were supplied with oral study med-
ication (isotretinoin or placebo) monthly, and instructed to store
the medication at room temperature. Any unused capsules were
returned at each visit. Compliance was calculated at the end of the
trial from pill counts and was defined on the basis of the intake of
blinded studymedication (isotretinoin/placebo). For each patient,
a compliance ratio (actual cumulative medication intake/sched-
uled cumulative medication intake) was calculated. In the case of
missing data, themedication intake was set to zero. Patients with a
compliance ratio less than 70% were excluded from the per-
protocol population.
Follow-Up Evaluation
After end of treatment patients were evaluated monthly for 3
months and than every 3 months until the third year after study
initiation. Afterward, visits took place every 6months until 5 years
after study initiation.
Disease-free status was maintained when there was no
hint of disease progression by either clinical assessment or imag-
ing procedures.
Statistics
The main analysis was performed for all randomized pa-
tients. Survival and disease-free survival were compared between
the treatment groups with the log-rank test (SAS procedure LIFE-
TEST; SAS Institute, Cary, NC) at the two-sided level .05. Disease-
free survival was defined as the time from start of treatment to the
time of progression or death, whichever occurred first.
Patients whowere lost to follow-upwere censored at the time
of the last observation. Kaplan-Meier curves and 5-year survival
rates with 95% CIs including CIs for the differences in the 5-year
survival rates were calculated. In addition, a multivariate analysis
was performed based on the proportional hazards model, with
stratification by center and using as covariables melanoma stage,
sex, age, and weight. Centers that recruited 20 or fewer patients
were combined (summarized) to a group (small centers) per
country. Patients from Greece and the Netherlands were com-
bined in a single group. For the subgroup of patients for whom
sentinel lymph node biopsy results were available, an additional
analysis was performed using a proportional hazards model with
the additional factor sentinel lymph-node-positive/negative. Dif-
ferences between the treatment groups in quality of life during
treatmentwere testedwith an independent samples t test, compar-
ing the area under the curve relative to the baseline value of the
quality-of-life measurements on a visual analog scale. The rates of
patients experiencing adverse events were compared with 2 tests.
Missing values were imputed according to the last observation
carried forward principle. In the interim analysis a significance
level of .01 (two-sided) was applied. Additionally, it was laid down
to stop the study for futility if the conditional power (assuming a
difference of 10% in the proportion of disease-free patients after 5
years) was less than 20%. The level for the final analysis was set to
.05 (two-sided).
Sample Size
A total sample size of 400 patients was planned, which would
give a power of approximately 80% for detecting a 10% difference in
5-year disease-free survival rate, assuming a 75%disease-free survival
rate in theplacebogroup, a recruitmentperiodof 4years, a total study
period of 9 years, and exponential disease-free survival.
Collection of Data and Data Management
Regular monitoring of the investigational sites was per-
formed. The data were stored in a relational database (Oracle)
located in the Statistical Center at the Department of Medical
Statistics at the University of Vienna. The database was closed on
February 29, 2004.
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RESULTS
Patients
A total of 407 patients were recruited, with 206 patients
randomly assigned to the isotretinoin group and 201 pa-
tients randomly assigned to the placebo group. Baseline
characteristics of the patients are listed in Table 1.
The 407 patients were recruited in 20 centers as follows:
368 patients from 11 centers in Austria, 34 patients from
seven centers in Hungary, three patients from one center in
Greece, and two patients from one center in the Nether-
lands. The median number of recruited patients of the six
largest centers was 40 patients, and six centers recruited
three patients or fewer.
Interim Analysis
A scheduled interim analysis performed 9months after
the end of the recruitment period showed a conditional
power of only 1.3%, far below the threshold 20% laid down
in the protocol. Consequently, a decision was made to stop
the trial immediately for futility, to examine the patients
currently enrolled, and to performafinal analysis within the
next 3 months.
Final Analysis
Disease-free survival. Disease progression was ob-
served in 67 patients in the isotretinoin group and in 53
patients in the placebo group, and two patients in each
group died without progression. There was no significant
difference in disease-free survival between the treatment
groups (P  .25, log-rank test, two sided). The 5-year
disease-free survival rates were 55% (95% CI, 46% to 65%)
in the isotretinoin group and 67% (95%CI, 59% to 75%) in
the placebo group (Fig 1). The rounded difference in the
5-year disease-free survival rates was11 percentage points
(95% CI,24% to 1%).
Table 1. Baseline Characteristics of the Patients Enrolled in the Study
Characteristic
Placebo Isotretinoin Total
No. % No. % No. %
No. of patients 201 49.4 206 50.6 407 100
Sex
Male 98 48.8 117 56.8 215 52.8
Female 103 51.2 89 43.2 192 47.2
Stage
IIA 155 77.1 146 70.9 301 74.0
IIB 46 22.9 60 29.1 106 26.0
Clark level
Not available 21 10.5 21 10.2 42 10.3
III 30 14.9 39 18.9 69 17.0
IV 139 69.2 134 65.1 273 67.1
V 11 5.5 12 5.8 23 5.7
Breslow, mm
Not available 17 8.5 20 9.7 37 9.1
1.5-2.0 70 34.8 63 30.6 133 32.7
2.01-3.0 49 24.4 50 24.3 99 24.32
3.01-4.0 28 13.9 28 13.6 56 13.8
 4.0 37 18.4 45 21.8 82 20.2
Localization
Not available 19 9.5 18 8.7 37 9.1
Head and neck 13 6.5 22 10.7 35 8.6
Extremities 73 36.3 69 33.5 142 34.9
Trunk 96 47.8 97 47.1 193 47.4
Sentinel biopsy
Not available 121 60.2 128 62.1 249 61.2
Negative 59 29.4 57 27.7 116 28.5
Positive 21 10.5 21 10.2 42 10.3
Age, years
Mean 51.9 53.3 52.6
SD 13.1 14.4 13.8
Range 18-74 19-75 18-75
Weight, kg
Mean 76.8 77.7 77.3
SD 15.9 14.9 15.4
Range 46-127 47-134 46-134
Abbreviation: SD, standard deviation.
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Overall survival. Survival rates did not differ signifi-
cantly between the treatment groups (P  .8). During the
study period, a total of 57 patients (30 in the isotretinoin
group and 27 in the placebo group) died, 53 of these pa-
tients (28 in the isotretinoin group and 25 in the placebo
group) from disseminated melanoma. The 5-year survival
rates were 76% in the isotretinoin group (95% CI, 67% to
84%) and 81% in the placebo group (95%CI 74% to 88%).
The difference in the 5-year survival rates was5 percent-
age points (95% CI,16% to 6%).
Prognostic factors. In the multivariate analysis, the
only significant prognostic factors were stage (P  .0001;
hazard ratio for stages IIB/IIA 2.33; 95%CI, 1.60 to 3.39)
and sex (P  .027; hazard ratio for male/female  1.62;
95% CI, 1.06 to 2.50). The multivariate analysis showed
no significant differences between the treatment groups
(P .81; hazard ratio for isotretinoin/placebo 1.05; 95%
CI, 0.72 to 1.52).
Figure 2 shows the Kaplan-Meier estimates by stage
(IIA v IIB) and sex. Clearly there was a worse prognosis for
stage IIB. Sex seemed to be an independent prognostic
factor, with men showing an inferior outcome compared
with women.
The analysis for the 158 patients for whom sentinel
lymph node biopsy results were available showed no signif-
icant differences between treatment groups (P  .39; haz-
ard ratio for isotretinoin/placebo  1.41; 95% CI, 0.65 to
3.08). Stage was again a significant prognostic factor
(P .02; hazard ratio for stage IIB/IIA 2.52; 95%CI, 1.16
to 5.48), and significantly worse prognosis was seen for
patients with positive sentinel lymph node (P .02; hazard
ratio for sentinel lymph node–positive/negative  2.31;
95% CI, 1.15 to 4.67).
Per-Protocol Analysis
As specified in the analysis plan, the data were also
analyzed in the per protocol population. This analysis con-
firms the findings from the all randomized patient popula-
tion. Reasons for exclusion from the per-protocol
population were laid down in a blinded review. A total of
173 patients (isotretinoin group, n 90; placebo group, n
 83) were excluded from the per-protocol population,
with no substantial difference in the exclusion pattern un-
der isotretinoin and placebo. A detailed flow chart of the
reasons of exclusion from the per-protocol population is
shown in Figure 3.
In the per-protocol analysis with the remaining 234
patients, no significant differences were detected in ei-
ther disease-free survival or overall survival (P .61 and
P  .25, respectively, log-rank test, two sided). The
5-year disease-free survival rates were 65% (95%CI, 54%
to 76%) in the isotretinoin group and 71% (95%CI, 62% to
80%) in the placebo group. The difference in the 5-year
disease-free survival rates was6 percentage points (95% CI,
20% to 8%).
The 5-year survival rates were 83% (95% CI, 74% to
92%) in the isotretinoin group and 77% (95% CI, 66% to
88%) in the placebo group. The difference in the 5-year sur-
vival rates was 7 percentage points (95%CI,8% to 21%).
Adverse Events
Ahigher number of adverse events were reported in the
isotretinoin group (889 events) than in the placebo group
(740 events). This differencewas due to higher incidences in
the isotretinoin group versus the placebo group of both chei-
litis/xerosis (175 v 44 events, respectively) and hyperlipidemia
(56v34events, respectively). 84%percentof thepatients in the
placebo group and 91% of the patients in the isotretinoin
group observed at least one adverse event (P .03).
Fig 1. Kaplan-Meier estimate of disease-free survival in all 407 randomly
assigned patients (P  .25, log-rank test, two sided). The Nos. above the
time axis indicate the patients still at risk. The bars give pointwise 95% CIs.
Fig 2. Kaplan-Meier estimate of disease-free survival in all 407 randomly
assigned patients by stage and sex (P  .001, log-rank test, two sided). The
Nos. above the time axis indicate the patients still at risk.
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Table 2 lists serious adverse events (WHO grades 3 or
4) reported in the study. Twenty-one percent of the patients
in both the placebo and the isotretinoin group experienced
at least one adverse event of grade 3 or 4 (P close to 1.00).
Three life-threatening adverse events (WHO grade 4) were
observed during the study. In the placebo group, one pa-
tient experienced an ischemic brain stroke after 1 month of
treatment, and one patient experienced dyspnea at the start
of treatment. In both patients treatment was stopped im-
mediately, and both patients showed complete recovery. In
the isotretinoin group, one patient experienced severe de-
pression after 6 months of treatment. Treatment was con-
tinued along with antidepressant medication and the
patient recovered. Similar numbers ofWHOgrade 3 serious
adverse events were reported in the isotretinoin group (67
events) and in the placebo group (80 events).
Minimal tomoderate adverse events (WHOgrades 1 to
2), including laboratory disorders, general disorders, skin
and tissue disorders, infection, inflammation, gastrointes-
tinal disorders, hormonal disorders, neurologic disorders,
cardiac disorders, circulatory disorders, and ophthalmo-
logic disorders were seen in 821 reports in the isotretinoin
group and in 658 reports in the placebo group. All disorders
were distributed equally within both groups with the excep-
tion of cheilitis/xerosis and hyperlipidemiamore often seen
in the isotretinoin group.
One patient became pregnant during the study. Treat-
ment was immediately stopped, and the treatment assign-
mentwas unblinded by the center, revealing that the patient
had been in the placebo group. This patient had a sponta-
neous abortion after 4months. Another patient, this time in
the isotretinoin group, became pregnant 6 months after
treatment cessation and delivered a healthy boy.
Four patients (two in each group) died of causes unre-
lated to melanoma. One patient in the isotretinoin group
Fig 3. Flow chart showing reasons of exclusion from the per-protocol analysis.
Table 2. Adverse Events Assessed As WHO Grade 3 or 4
Adverse Event (WHO grade 3 or 4)
No. of Events
Placebo
Group
(n  44)
Isotretinoin
Group
(n  45)
WHO grade 4
Total 2 1
Ischemic brain stroke 1 0
Dyspnea 1 0
Depression 0 1
WHO grade 3
General disorders (total) 17 10
Flu-like symptoms 8 8
Tooth pain 4 0
Sleeping disorders 3 0
Others (taste alteration, hearing loss,
weight loss, hair loss)
2 2
Skin and tissue disorders (total) 4 13
Cheilitis and xerosis 2 12
Others (exanthema, aggravation of
psoriasis)
2 1
Laboratory disorders (total) 10 17
Leucopenia 1 3
Elevation of liver enzymes 3 0
Hyperlipidemia 4 12
Others (anemia, thrombopenia, increase of
creatinin phosphokinase)
2 2
Inflammation and infection (total) 10 7
Inflammation 3 4
Infection 6 3
Others (polyarthritis) 1 0
Gastrointestinal and renal disorders (total) 5 2
Pancreatitis, diarrhea, cholecystolithiasis,
nephrolithiasis, gastritis
5 2
Hormonal disorders, total 10 3
Menstrual disorders 9 1
Others (impotence, hypothyreosis) 1 2
Neurological disorders, total 13 9
Depression 1 3
Migraine 10 3
Others (paresis, neuritis, Grand Mal epilepsy) 2 3
Cardiac disorders, total 5 2
Angina pectoris 4 1
Other (hypertension) 1 1
Circulatory disorders, total 4 2
Thrombosis 2 2
Other (bleeding) 2 0
Musculoskeletal disorders, total 2 1
Hernia inguinalis, herniated disk 1 0
Ophthalmologic disorders, total 0 1
Vitreous floaters 0 1
Total 80 67
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died of cardiac decompensation 33 months after the end of
treatment. A second patient in the isotretinoin group died
of myocardial infarction 13months after start of treatment.
In the placebo group, one patient died in a car accident and
one patient died of cholangiocellular carcinoma. None of
the four deaths were considered drug-related.
Quality of Life
Quality-of-life measurements at baseline, 6 months,
and 2 years were available for 68%, 63%, and 31% of the
patients with only marginal differences between treatment
groups.Theareaunder thebaselinevalues for thevisual analog
scale to evaluate quality of life showedno significant difference
between treatment groups (P .94, two-sided t test).
Secondary Malignancies
Secondary malignancies reported in the isotretinoin
group (five patients) included secondary melanoma (three
patients), basal cell carcinoma (one patient), and gastric
cancer (one patient). Secondary malignancies reported in
the placebo group (10 patients) included basal cell carci-
noma (four patients), squamous cell carcinoma (one pa-
tient), breast cancer (one patient), cholangiocellular
carcinoma (one patient), mixed carcinoma (one patient),
multiple myeloma (one patient), and cervical dysplasia
(one patient).
DISCUSSION
The optimal care formelanoma patients withmoderate and
high risk to develop metastasis (stage IIA and IIB AJCC/
UICC 1988)37 and for patients with micrometastasis in the
sentinel lymphnode (stage IIIAAJCC)5 has been amatter of
debate.6,10,11,14,39,40 IFN is the drug most frequently pre-
scribed for adjuvant treatment of melanoma, but currently
there is no consensus on the optimal regimen. Prolongation
of overall survival in patients with moderate and high risk
has been demonstrated in studies evaluating high-dose
IFN treatment.6,12-14,41 However, although high-dose
IFN treatment regimens are widely used in the United
States and, according to some, should be the gold standard
of adjuvant therapy,4,40 the high cost of high-dose IFN
treatment, the toxicity profile (leading in some cases to the
death of disease-free patients),42,43 and conflicting efficacy
results have created a dilemma for dermatologists and on-
cologists practicing in Europe. Consequently, low- and
intermediate-dose IFN regimens are still under consider-
ation in Europe.14 Some studies evaluating treatment of this
patient population with low-dose IFN showed prolonga-
tion of disease-free survival,7-9 but others did not.13,14,44
The question “high-dose, low-dose, no dose, which dose?” for
the adjuvant treatment39 has not yet been resolved, although
low-dose IFN at a dose of 3 MU 3 times a week is registered
for adjuvant treatment in the participating countries.
The aim of our study was not to attempt to resolve the
issue of optimal IFN dosage, but to look carefully at the
question of whether the addition of another active antitu-
mor agent to an adjuvant low-dose IFN regimen widely
used in Europe could significantly improve both disease-
free survival and overall survival in patients with moderate
to high risk of developing metastatic disease. We chose to
add isotretinoin, a derivate of retinoic acid, with sebosup-
pressive, anti-inflammatory, cell differentiation, and im-
munomodulatory functions, which has been shown to be
effective in the treatment of severe acne and other inflam-
matory diseases.16,18 In both laboratory studies and clinical
trials, retinoids have been shown to have antineoplastic
activity, inhibiting growth of tumor cells directly or by
induction of differentiation, inhibiting cell invasion ofmel-
anoma cells, influencing the expression of tumor cell sur-
face markers, and inducing apoptosis in leukemic and solid
tumor cells.16-20,45
Our patient population consisted of patients in stage
IIA and stage IIB, based on the definition of localized mel-
anoma with tumor thickness from 1.51 to 4.0 mm or Clark
level IV (IIA) or localized melanoma with tumor thickness
greater than 4.0 mm or Clark level V (IIB) without nodal
metastases (AJCC/UICC 1988).37 A total of 301 patients
(74%) were in stage IIA and 106 patients (26%) were in
stage IIB, a percentage also comparable to both other large
studies in those stages of the Austrian and the French
groups.7,8 During the course of the study, the definitionwas
modified to include also patients with micrometastasis in
the sentinel lymph node and the study protocol was
amended to permit the enrollment of those patients. Simi-
lar numbers of men and women were enrolled onto the
study, with a slight predominance of men (53%), as also
seen in other studies.7,8
Patients with stage IIA to IIB disease have an estimated
5-year disease-free survival rate between 45% and 50%
without any treatment and between 57% and 66% with
low-dose IFN treatment.7,8 Disease-free survival of our
study population overall was within the expected range at
61% (95% CI, 55% to 67%), with no significant difference
between the isotretinoin and placebo groups (55% and
67%, respectively; P  .25). Similarly, estimated 5-year
survival of our study population was within the expected
range and was equivalent in the two treatment groups
(76%, isotretinoin group; 81%, placebo group; P .8). The
lack of efficacy of isotretinoin in this regimen might reflect
the heterogeneous response of melanoma cells to isotreti-
noin treatment, as shown in variable response rates of mel-
anoma cell lines in laboratory studies24,25 and in conflicting
efficacy results seen in clinical trials in patients with meta-
static melanoma.27,30,32,33,35,36 Response proportion and
survival was also not improved in a study in patients with
advanced renal cell carcinoma.46
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Sentinel node positivity is found in up to 30% of pa-
tients with stage IIA and IIB melanoma.47-49 In our study
population, sentinel positivity was detected in 42 (27%) of
158 patients for whom sentinel node biopsy results were
available. The multivariate analysis accounting for positive
sentinel biopsy confirmed the overall negative study result.
Consistent with results reported earlier,50,51 our analysis
showed melanoma stage and patient sex to be the only
significant prognostic factors. In the subgroup where senti-
nel node biopsy results were available, sentinel node posi-
tivity was an independent negative prognostic factor for
disease-free survival.
A limitation of the study is that disease-free survival
instead of overall survival has been used as the primary end
point. However, when looking at our data, we see that from
120 patients with progression as defined in the study, ap-
proximately 44% died in the observation period. Of the 287
patients who had no progression, only four patients died.
Hence, our data show a close relationship between progres-
sion and survival.
In conclusion, in our study, the addition of isotretinoin
to a 2-year low-dose IFN treatment did not have any
impact on either disease-free survival or on overall survival
in patients with malignant melanoma stage IIA and IIB
AJCC/UICC 1988.
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